Minze Health

TLDR

Minze Health is an Antwerp-based digital therapeutics company focused on urology and incontinence treatment, with $9.2M in total funding from White Fund, Capricorn, PMV, and imec.istart.

Overview

Based in Antwerp, Minze Health develops clinically validated Prescription Digital Therapeutics (PDTs) for urological conditions including bladder dysfunction and incontinence, affecting hundreds of millions of patients globally. The company's solutions are used by over 160,000 patients across 20+ countries, trusted by clinicians as a complement or alternative to pharmacological treatments for lower urinary tract symptoms (LUTS).

Minze raised EUR 3.9M in December 2022 from White Fund, Capricorn Partners, and PMV. In October 2024, the company secured an additional USD 5.3M from the same core syndicate, joined by imec.istart Future Fund as a new investor, bringing total funding to approximately USD 9.2M. In September 2025, Minze entered a strategic collaboration with Apogepha (Germany) to develop a digital therapeutic specifically for male LUTS.

The urology-focused digital therapeutics category is commercially promising given aging demographics across Western Europe and the US, and growing payer and provider interest in validated behavioral and software-based interventions.

Key People

• Gilles Tas - Co-founder
• Jiri Vermeulen - Co-founder
• Thomas Moore - CEO

Funding History

• December 2022: EUR 3.9M from White Fund, Capricorn Partners, PMV
• October 2024: USD 5.3M from White Fund, Capricorn Digital Growth Fund, PMV, imec.istart Future Fund